adapalene vs tacrolimus topical
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of adapalene and tacrolimus topical. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Differin
Protopic
No summary available.
Tacrolimus extended-release capsules help prevent organ rejection in kidney transplant patients. It works by suppressing your immune system.
Information not available.
This medicine is used to prevent your body from rejecting a new kidney after a transplant. It is for adult patients who can swallow capsules whole. You will take it with other medicines that also suppress your immune system.
Information not available.
Tacrolimus belongs to a class of drugs called calcineurin inhibitors. It lowers the activity of your immune system. This helps prevent your body from attacking your new kidney.
- • Dry skin
- • Contact dermatitis (skin rash)
- • Burning feeling on the skin where you put the medicine
- • Skin irritation
- • Diarrhea
- • Constipation
- • Nausea
- • Swelling in your arms and legs
- • Tremors
- Dry Skin 44,990
- Skin Burning Sensation 41,633
- Acne 39,264
- Erythema 38,379
- Skin Irritation 26,225
No adverse event reports.
No specific warnings noted.
This medicine can increase your risk of serious infections and certain cancers. These problems could lead to hospitalization or even death. This drug is not approved for liver transplants and may increase the risk of death in female liver transplant patients.
No pregnancy information available.
Tacrolimus can harm your unborn baby. Tell your doctor right away if you are pregnant or plan to become pregnant. There is a pregnancy registry to track outcomes in women who take tacrolimus during pregnancy.
Also Compare, Nearby Drugs
Compare adapalene with
Compare tacrolimus topical with
How to Read This adapalene vs tacrolimus topical Comparison
adapalene is classified in the Retinoid (Topical) drug class, while tacrolimus topical sits within the Calcineurin Inhibitor (Topical) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are split between OTC and prescription status, which affects access and supervision.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adapalene has 190,491 submissions while tacrolimus topical has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adapalene or tacrolimus topical.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.